

## Publications:

1. **Singh RK**, Sinha N, Jain S, Naqvi F, Salman M. and Anand N. Synthesis of optically active  $\alpha$ - heterocyclic  $\alpha$ -amino acids from activated lactams. Part-1. *Synthesis* 2005;16:2765-2771.
2. **Singh RK**, Sinha N, Jain S, Naqvi F, Anand N. Synthesis of optically active  $\beta$ -heterocyclic  $\beta$ -amino acids from activated lactam. Part-2. *Tetrahedron* 2005 61:8868-8874.
3. Satyan KS, Swamy N, Dizon DS, **Singh RK**, Granai CO, Brard L. Phenethyl isothiocyanate (PEITC) inhibits growth of ovarian cancer cells by inducing apoptosis: role of caspase and MAPK activation. *Gynecol Oncol* 2006;103:261-270.
4. **Singh RK**, Sinha N, Jain S, Naqvi F, Mehta A and Anand N. A general and efficient synthesis of 3,6-diazabicyclo[3.2.1]octanes. *Tetrahedron* 2006; 62:4011-4017.
5. Brard L, Robison K, **Singh RK**, Kim KK, Lange TS A novel non-hypercalcemic vitamin D derivative in the treatment of ovarian cancer. *J Wom Health* 2007; 16:1098-1099.
6. **Singh RK**, Jain S, Sinha N, Mehta A, Naqvi F, Agarwal AK and Anand N. A simple and efficient synthesis of 8-methyl-3, 8-diazabicyclo[3.2.1]octane (azatropane) and 3-substituted azatropanes therefrom using pyroglutamic acid. *Tet Lett* 2007;48:545-548.
7. Lange TS, **Singh RK**<sup>S</sup>, Kim KK, Zou Y, Kalkunte SS, Sholler GS, Swamy N, Brard L Anti-proliferative and pro-apoptotic Properties of 3-Bromoacetoxy Calcidiol (B3CD) in High-Risk Neuroblastoma. *Chem Biol Drug Design* 2007; 70:302-310.
8. **Singh RK**, Lange TS, Kim KK, Zou Y, Lieb C, Brard L Effect of Indole Ethyl Isothiocyanates on proliferation, apoptosis and MAPK signaling in neuroblastoma cell lines. *Bioorg Med Chem Lett* 2007;17:5846-5852.
9. Koto K, Brard L, Bosenberg M, **Singh RK**, Kim KK, Scholler GS. RKS-2-62: A novel therapy for medulloblastoma with activity in vitro and in vivo. *Neurooncology* 2008;10: 513-514.
10. **Singh RK**, Lange TS, Kim KK, Singh AP, Vorsa N, Brard L. Isothiocyanate NB7M causes selective cytotoxicity, pro-apoptotic signaling and cell cycle regression in ovarian cancer cells. *Br J Cancer* 2008;99:1823–1831.
11. Lange TS, Kim KK, **Singh RK**, Strongin RM, Mc Court C, Brard L. Iron-Salophene: An organo-metallic compound with selective cytotoxic and anti-proliferative properties in platinum-resistant ovarian cancer cells. *PLOS One* 2008;3;5: e2303.
12. Brard L, **Singh RK**<sup>S</sup>, Kim KK, Lange TS, Sholler GS. Induction of Cytotoxicity, Apoptosis and Cell Cycle Arrest by 1-t-Butyl Carbamoyl, 7-Methyl-Indole-3-Ethyl Isothiocyanate (NB7M) in Nervous System Cancer Cells. *Drug Design, Development and Therapy* 2008;2:61-69.
13. **Singh RK**, Lange TS, Kim KK, Singh AP, Hopson R, Vorsa N, Brard L. Synthesis of Bicyclic Aryl Thiazolines with selective anti-proliferative effects on human cancer cell lines. *Lett Org Chem* 2008;5:103-109.

14. Singh RK, Lange TS, Shaw S, **Kim KK**, Brard L. A novel Indole Ethyl Isothiocyanate (7Me-IEITC) with anti-proliferative and pro-apoptotic effects on platinum-resistant ovarian cancer cells. *Gynecol Oncology* 2008;109:240-249.
15. Singh AP, **Singh RK**<sup>§</sup>, Kim KK, Kalkunte KS, Vorsa N, Brard L. Cranberry Proanthocyanidines sensitize the ovarian cancer cells to platinum Therapy. *Phytother Res* 2009;23:1066-1074.
16. Lange TS, McCourt C, **Singh RK**, Stuckey AR, Singh AP, Alturk O, Strongin RM, Brard L. Pro-apoptotic and chemotherapeutic properties of Iron-salophene in an ovarian-cancer animal model. *Drug Des Dev Ther* 2009;3:17–26.
17. Lange TS, Stuckey AR, Robison K, Kim KK, **Singh RK**, Baker CA, Brard L. Effect of B3CD, a novel Vitamin D derivative with postulated anti-cancer activity in an ovarian cancer animal model. *Invest New Drugs*. 2010;28:543-553.
18. Lange TS, Zou Y, **Singh RK**, Kim KK, Kristjansdottir K, Saulnier Sholler GL, Brard L. Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model. *Chem Biol Drug Des*. 2010 Aug;76(2):164-173.
19. Kim KK, Lange TS, **Singh RK**, Brard L. Lipophilic aroylhydrazone chelator HNTMB and its multiple effects on ovarian cancer cells. *BMC cancer* 2010; 10:72.
20. **Singh RK**, Lange TS, Kim KK. Brard L. RKS262 causes selective cytotoxicity, pro-apoptotic MAPKinase and selective BCl2 family signaling and cell-cycle regression in ovarian cancer cells. *Invest New Drugs* 2011;29(1):63-72.
21. Stuckey A, Fischer A, Miller DH, Hillenmeyer S, Kim KK, Ritz A, **Singh RK**, Raphael BJ, Brard L and Brodsky AS. Integrated Genomics of Ovarian Xenograft Tumor Progression and Chemotherapy Response. *BMC Cancer* 2011;11:308.
22. **Singh RK**, Dorf L, DeMartino A, Illeyne S, Koto KS, Ashikaga T, Kim KK, Sholler GLS, Brard L. (2011). Oral RKS262 Reduces Tumor Burden in a Neuroblastoma (NB) Xenograft Animal Model and Mediates Cytotoxicity through SAPK/JNK and ROS Activation in vitro. *Cancer Biol and Therapy* 2011;11(12):1036-45
23. Koto KS, Lescault P, Brard L, Kim KK, **Singh RK**, Bond J, Illeyne S, Slavik MA, Ashikaga T, Sholler GLS (2011). Antitumor and Genomic activity of nifurtimox is enhanced with tetrathiomolybdate in medulloblastoma in vitro. *Int J of Oncology*, 38:1329-1341.
24. Kim KK, **Singh RK**, Brard L, Moore R, Lange TS (2011). Proapptotic and cell cycle regulatory effects of novel Iron-salophenes in childhood neuroblastoma. *Plos-one* 2011;6(4):e19049.
25. Kim KK, Kawar NM, Lange TS, **Singh RK**, Moore RG. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. *Gynecol Oncol* 2011;122:183-189.
26. Brard L, Lange TS, Robison K, Kim KK, Ara T, McCallum MM, Arnold LA, Moore RG, **Singh RK**\*. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines. *Gynecol Oncol*. 2011;123:370-378.
27. Kim KK, Singh AP, **Singh RK**, Demartino A, Brard L, Vorsa N, Lange TS, Moore RG. Anti-angiogenic activity of cranberry proanthocyanidins and cytotoxic properties in ovarian cancer cells. *Int J Oncol* 2012;40:227-235.

28. Lange TS, Horan TC, Kim KK, Singh AP, Vorsa N, Brard L, Moore RG, **Singh RK\***. Cytotoxic properties of adamantyl isothiocyanate and potential in vivo metabolite adamantyl-N-acetylcystein in gynecological cancer cells. *Chem Biol Drug Des.* 2012;79:92-103.
29. Moore RG, Lange TS, Robinson K, Kim KK, Uzun A, Horan TC, Kawar Nada, Yano N, Chu SR, Mao Q, Brard L, DePaeppe ME., Padbury JF, Arnold LA, Brodsky A, Shen Tun-Li, **Singh RK\***. Efficacy of a non-hypercalcemic vitamin-D2 derived anti-cancer agent (MT19c) and inhibition of fatty acid synthesis in an ovarian cancer xenograft model. *PLoS ONE* 7(4): e34443.

#### Patents:

1. Palle VP, Verma A, **Singh RK**, Malhotra S, Waman YB, Walia A, Ray A, Sharma G. Azabicycloaminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as anti-inflammatory agents and their preparation and pharmaceutical compositions. PCT Int. Appl. (2006), WO 2006082492 A1.
2. Palle VP, **Singh RK**, Malhotra S, Waman YB, Verma A, Ray A, Sharma G. Preparation of pyrido[2,3-d]pyrimidines as anti-inflammatory agents. PCT Int. Appl. (2006), WO 2006056863 A1.
3. Palle VP, Verma AK, Salman M; **Singh RK**, Waman YB; Sharma G; Ray A. Preparation of heterocyclic derivatives as anti-inflammatory agents. PCT Int. Appl. (2006), WO 2006016237 A2.
4. Verma A, Malhotra S, **Singh RK**, Palle ABVP, Walia A, Sharma G. Novel anti-inflammatory agents: 2753/DEL/2006 (India).
5. Brard L, Kalkunte S, and **Singh RK**. Heterocycles and Derivatives thereof and methods of manufacture and therapeutic use: PCT/US 2006/047320.
6. Brard L, **Singh RK**, Kalkunte S, Strongins R, Onur A. Organometallic Complexes as therapeutic agents. WO/2008/070557(PCT/US2007/086080).
7. Scholler G, Kalkunte S, **Singh RK**, Kim KK, Lange TS, Brard L. nitrofurans compounds as potential anticancer and anti-angiogenic agents. PCT/US 2007/001527.
8. Brard L, **Singh RK**, Kim KK, Scholler G. N-Amino Tetrahydrothiazine derivatives, method of manufacture and use. WO/2008/091946 (PCT/US2008/051794).
9. Verma AK, Palle VP, Malhotra S, **Singh RK**, Walia A, Bajpai M, Chopra P, Ray A. Anti-inflammatory agents. WO/2008/078249.
10. Ray A, Palle VP, Verma A, **Singh RK**, Waman YB, Walia A, Sharma G. Azabicyclo derivatives as anti-inflammatory agents. US20090036472.
11. Ray A, Malhotra S, Palle VP, Verma A, **Singh RK**, Waman YB, Sharma G. Pyrido2',3-Dipyrimidines as anti-inflammatory agent. US20090131430.
12. Moore, RG, **Singh RK**. Adamantyl derivatives as therapeutic agents. US61/567,223.
13. Moore RG, **Singh RK**. HE4 based gene and antibody therapy of human diseases and malignancies, methods and applications. US61/493,881.